The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells

Journal of Photochemistry and Photobiology B: Biology

Volumn 117, Issue , 2012, Pages 115-125

  Šemeláková, Martina ^a   Mikeš, Jaromír ^a   Jendželovský, Rastislav ^a   Fedoročko, Peter ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Aristoforin; Hyperforin; Hypericin; PDT

Indexed keywords

ARISTOFORIN; CASPASE 3; GELATINASE A; GELATINASE B; HYPERFORIN; HYPERICIN; REACTIVE OXYGEN METABOLITE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CELL CYCLE PROGRESSION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPERICUM; MITOCHONDRIAL MEMBRANE POTENTIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SYNERGISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM INVASIVENESS; PERYLENE; PHLOROGLUCINOL; PHOTOCHEMOTHERAPY; REACTIVE OXYGEN SPECIES; TERPENES;

HYPERICUM;

EID: 84867637631     PISSN: 10111344     EISSN: 18732682     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2012.09.003     Document Type: Article

References (34)

1. P. Agostinis, Z. Assefa, A. Vantieghem, J.R. Vandenheede, W. Merlevede, and P. De Witte Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin Adv. Enzyme Regul. 40 2000 157 182
2. P. Agostinis, A. Vantieghem, W. Merlevede, and P.A. de Witte Hypericin in cancer treatment: more light on the way Int. J. Biochem. Cell Biol. 34 2002 221 241
3. C.J. Gomer, A. Ferrario, M. Luna, N. Rucker, and S. Wong Photodynamic therapy: combined modality approaches targeting the tumor microenvironment Laser Surg. Med. 38 2006 516 521
4. L. Kulikova, J. Mikes, M. Hyzdalova, G. Palumbo, and P. Fedorocko NF-kappaB is not directly responsible for photoresistance induced by fractionated light delivery in HT-29 colon adenocarcinoma cells Photochem. Photobiol. 86 2010 1285 1293
5. V. Sackova, L. Kulikova, J. Mikes, J. Kleban, and P. Fedorocko Hypericin-mediated photocytotoxic effect on HT-29 adenocarcinoma cells is reduced by light fractionation with longer dark pause between two unequal light doses Photochem. Photobiol. 81 2005 1411 1416
6. J. Kleban, J. Mikes, B. Szilardiova, J. Koval, V. Sackova, P. Solar, V. Horvath, J. Hofmanova, A. Kozubik, and P. Fedorocko Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells Photochem. Photobiol. 83 2007 1174 1185
7. C.A. Erdelmeier Hyperforin possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L Pharmacopsychiatry 31 Suppl 1 1998 2 6
8. L. Beerhues Hyperforin Phytochemistry 67 2006 2201 2207
9. I. Dell'Aica, R. Niero, F. Piazza, A. Cabrelle, L. Sartor, C. Colalto, E. Brunetta, G. Lorusso, R. Benelli, A. Albini, F. Calabrese, C. Agostini, and S. Garbisa Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis J. Pharmacol. Exp. Ther. 321 2007 492 500
10. M.A. Medina, B. Martinez-Poveda, M.I. Amores-Sanchez, and A.R. Quesada Hyperforin: more than an antidepressant bioactive compound? Life Sci. 79 2006 105 111
11. M. Dona, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, M. Della Barbera, A. Donella-Deana, G. Appendino, A. Borsarini, R. Caniato, and S. Garbisa Hyperforin inhibits cancer invasion and metastasis Cancer Res. 64 2004 6225 6232
12. M. Rothley, A. Schmid, W. Thiele, V. Schacht, D. Plaumann, M. Gartner, A. Yektaoglu, F. Bruyere, A. Noel, A. Giannis, and J.P. Sleeman Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo Int. J. Cancer 125 2009 34 42
13. C.M. Schempp, V. Kirkin, B. Simon-Haarhaus, A. Kersten, J. Kiss, C.C. Termeer, B. Gilb, T. Kaufmann, C. Borner, J.P. Sleeman, and J.C. Simon Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis Oncogene 21 1 2002 242 250
14. C.M. Schempp, B. Winghofer, R. Ludtke, B. Simon-Haarhaus, E. Schopf, and J.C. Simon Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells Brit. J. Dermatol. 142 2000 979 984
15. K. Hostanska, J. Reichling, S. Bommer, M. Weber, and R. Saller Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines Eur. J. Pharm. Biopharm. 56 2003 121 132
16. G. Lorusso, N. Vannini, I. Sogno, L. Generoso, S. Garbisa, D.M. Noonan, and A. Albini Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent Eur. J. Cancer 45 2009 1474 1484
17. M. Gartner, T. Muller, J.C. Simon, A. Giannis, and J.P. Sleeman Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent Chembiochem 6 2005 171 177
18. D. Albert, I. Zundorf, T. Dingermann, W.E. Muller, D. Steinhilber, and O. Werz Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase Biochem. Pharmacol. 64 2002 1767 1775
19. C. Feisst, D. Albert, L. Verotta, and O. Werz Evaluation of hyperforin analogues for inhibition of 5-lipoxygenase Med. Chem. 1 2005 287 291
20. J. Kleban, B. Szilardiova, J. Mikes, V. Horvath, V. Sackova, P. Brezani, J. Hofmanova, A. Kozubik, and P. Fedorocko Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin J. Photochem. Photobiol. 84 2006 79 88
21. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
22. M. Niyazi, I. Niyazi, and C. Belka Counting colonies of clonogenic assays by using densitometric software Radiat. Oncol. 2 2007 4
23. P. Ferenc, P. Solar, J. Kleban, J. Mikes, and P. Fedorocko Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells J. Photochem. Photobiol. 98 2010 25 34
24. R. Jendzelovsky, J. Mikes, J. Koval, K. Soucek, J. Prochazkova, M. Kello, V. Sackova, J. Hofmanova, A. Kozubik, and P. Fedorocko Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells Photochem. Photobiol. Sci. 8 2009 1716 1723
25. G. Kroemer Mitochondrial control of apoptosis: an introduction Biochem. Biophys. Res. Commun. 304 2003 433 435
26. K. Leuner, V. Kazanski, M. Muller, K. Essin, B. Henke, M. Gollasch, C. Harteneck, and W.E. Muller Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels Faseb J. 21 2007 4101 4111
27. K. Treiber, A. Singer, B. Henke, and W.E. Muller Hyperforin activates nonselective cation channels (NSCCs) Brit. J. Pharmacol. 145 2005 75 83
28. B. Bauvois New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression Biochem. Biophys. Acta 2012 1825 29 36
29. R. Roy, J. Yang, and M.A. Moses Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer J. Clin. Oncol. 27 2009 5287 5297
30. M. Rydlova, L. Holubec Jr., M. Ludvikova Jr., D. Kalfert, J. Franekova, C. Povysil, and M. Ludvikova Biological activity and clinical implications of the matrix metalloproteinases Anticancer Res. 28 2008 1389 1397
31. T. Turpeenniemi-Hujanen Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers Biochimie 87 2005 287 297
32. J. Bialek, U. Kunanuvat, S. Hombach-Klonisch, A. Spens, J. Stetefeld, K. Sunley, D. Lippert, J.A. Wilkins, C. Hoang-Vu, and T. Klonisch Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells Mol. Cancer Res. 9 2011 673 687
33. B. Martinez-Poveda, A.R. Quesada, and M.A. Medina Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process Int. J. Cancer 117 2005 775 780
34. A. Liu, H. Chen, W. Wei, S. Ye, W. Liao, J. Gong, Z. Jiang, L. Wang, and S. Lin Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer Oncol. Rep. 26 2011 81 89